A computer didn’t just help design the latest vaccine to enter human trials. It built the thing from scratch. And scientists at Cambridge say that’s never happened before.
Researchers at the university have announced they’ve completed the first-ever human trial of a vaccine that was conceived and designed entirely by artificial intelligence. The target? A strain of bacteria called Group A Streptococcus, which kills around 500,000 people globally every year and has, until now, resisted every attempt to produce a working vaccine.
The AI system sifted through thousands of bacterial proteins, identifying which fragments were most likely to trigger a strong immune response in humans. What would have taken a team of scientists several years to work through manually, the system apparently completed in a fraction of the time.
Dr. Landscape, one of the lead researchers, described the result as “a proof of concept that changes how we think about vaccine discovery.” The early-phase trial, which tested safety and immune response in a small group of healthy volunteers, reportedly showed promising results, though full efficacy data is still some way off.
It’s not as though AI has been absent from medicine up to this point. It’s already being used to spot cancers in scans, predict patient deterioration in ICUs, and accelerate drug discovery. But having it actually author a vaccine candidate, rather than assist a human doing so, is a meaningful step further.
Sceptics will note, fairly, that early-phase trials are a long way from a licensed jab sitting in a GP’s fridge. The history of vaccine development is littered with candidates that looked brilliant at phase one and fell apart later. Caution is warranted.
Still, the implications are hard to ignore. Group A Strep alone causes over 600 million infections a year. If AI can crack that, the question becomes: which disease is next on the list?
For now, Cambridge’s team will press on with further trials. But the more interesting question might not be whether this particular vaccine works. It’s whether we’re watching the moment that drug discovery quietly became a different profession.
